Skip to main content

Articles

Page 4 of 39

  1. The prevalence of patients with concomitant cardiovascular disease and diabetes mellitus (DM) is increasing rapidly. We aimed to compare the effectiveness of current cardiac rehabilitation (CR) programs across...

    Authors: Prisca Eser, Thimo Marcin, Eva Prescott, Leonie F. Prins, Evelien Kolkman, Wendy Bruins, Astrid E. van der Velde, Carlos Peña-Gil, Marie-Christine Iliou, Diego Ardissino, Uwe Zeymer, Esther P. Meindersma, Arnoud. W. J. Van’tHof, Ed P. de Kluiver, Markus Laimer and Matthias Wilhelm

    Citation: Cardiovascular Diabetology 2020 19:37

    Content type: Original investigation

    Published on:

  2. The present cohort study aims to examine the relationship between fibrinogen (Fib) levels and glucose metabolism [fasting blood glucose (FBG) and hemoglobin A1c (HbA1c)] and investigate the impact of high Fib ...

    Authors: Shuo-Lin Liu, Na-Qiong Wu, Hui-Wei Shi, Qian Dong, Qiu-ting Dong, Ying Gao, Yuan-Lin Guo and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2020 19:36

    Content type: Original investigation

    Published on:

  3. Data on the relationship between the triglyceride glucose (TyG) index and coronary artery calcification (CAC) progression is limited. This longitudinal study evaluated the association of TyG index with CAC pro...

    Authors: Ki-Bum Won, Eun Ji Park, Donghee Han, Ji Hyun Lee, Su-Yeon Choi, Eun Ju Chun, Sung Hak Park, Hae-Won Han, Jidong Sung, Hae Ok Jung and Hyuk-Jae Chang

    Citation: Cardiovascular Diabetology 2020 19:34

    Content type: Original investigation

    Published on:

  4. The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the live...

    Authors: Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu and Dan-Yan Xu

    Citation: Cardiovascular Diabetology 2020 19:33

    Content type: Review

    Published on:

  5. Biomarkers may contribute to our understanding of the pathophysiology of various diseases. Type 2 diabetes (T2D) and coronary heart disease (CHD) share many clinical and lifestyle risk factors and several biom...

    Authors: Cornelia Huth, Alina Bauer, Astrid Zierer, Julie Sudduth-Klinger, Christa Meisinger, Michael Roden, Annette Peters, Wolfgang Koenig, Christian Herder and Barbara Thorand

    Citation: Cardiovascular Diabetology 2020 19:32

    Content type: Original investigation

    Published on:

  6. The triglyceride glucose (TyG) index, a simple surrogate estimate of insulin resistance, has been demonstrated to predict cardiovascular (CV) disease morbidity and mortality in the general population and many ...

    Authors: Xiaoteng Ma, Lisha Dong, Qiaoyu Shao, Yujing Cheng, Sai Lv, Yan Sun, Hua Shen, Zhijian Wang, Yujie Zhou and Xiaoli Liu

    Citation: Cardiovascular Diabetology 2020 19:31

    Content type: Original investigation

    Published on:

  7. Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, w...

    Authors: Yi-Hsin Chan, Chi Chuang, Cze-Ci Chan, Hsin-Fu Lee, Ya-Chi Huang, Yu-Tung Huang, Shang-Hung Chang, Chun-Li Wang, Tze-Fan Chao, Chi-Tai Kuo, Yung-Hsin Yeh and Shih-Ann Chen

    Citation: Cardiovascular Diabetology 2020 19:30

    Content type: Original investigation

    Published on:

  8. The study regarding load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction is very interesting. But there are a few thing...

    Authors: Bo Liang, Yu-Xiu Zhao and Ning Gu

    Citation: Cardiovascular Diabetology 2020 19:29

    Content type: Commentary

    Published on:

  9. The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes a...

    Authors: Lin Zhu, Andrew Hayen and Katy J. L. Bell

    Citation: Cardiovascular Diabetology 2020 19:28

    Content type: Original investigation

    Published on:

  10. High soluble suppression of tumorigenicity-2 (sST2) is a marker of poor prognosis in chronic inflammatory conditions. ST2 and its ligand interleukin (IL)-33 are elevated in adipose tissue of obese individuals....

    Authors: Svitlana Demyanets, Christoph Kaun, Alexandra Kaider, Walter Speidl, Manfred Prager, Stanislav Oravec, Philipp Hohensinner, Johann Wojta and Gersina Rega-Kaun

    Citation: Cardiovascular Diabetology 2020 19:26

    Content type: Original investigation

    Published on:

  11. The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivit...

    Authors: Charles E. Leonard, Colleen M. Brensinger, Ghadeer K. Dawwas, Rajat Deo, Warren B. Bilker, Samantha E. Soprano, Neil Dhopeshwarkar, James H. Flory, Zachary T. Bloomgarden, Joshua J. Gagne, Christina L. Aquilante, Stephen E. Kimmel and Sean Hennessy

    Citation: Cardiovascular Diabetology 2020 19:25

    Content type: Original investigation

    Published on:

  12. Obesity, hypertension and prediabetes contribute greatly to coronary artery disease, heart failure and vascular events, and are the leading cause of mortality and morbidity in developed societies. Salt sensiti...

    Authors: Vijayakumar Sukumaran, Hirotsugu Tsuchimochi, Takashi Sonobe, Mark T. Waddingham, Mikiyasu Shirai and James T. Pearson

    Citation: Cardiovascular Diabetology 2020 19:24

    Content type: Original investigation

    Published on:

  13. Many studies have reported the predictive value of the atherogenic index of plasma (AIP) in the progression of atherosclerosis and the prognosis of percutaneous coronary intervention (PCI). However, the utilit...

    Authors: Zheng Qin, Kuo Zhou, Yueping Li, Wanjun Cheng, Zhijian Wang, Jianlong Wang, Fei Gao, Lixia Yang, Yingkai Xu, Yafeng Wu, Hua He and Yujie Zhou

    Citation: Cardiovascular Diabetology 2020 19:23

    Content type: Original investigation

    Published on:

  14. Little is known about whether mitochondria 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of mitochondrial DNA (mtDNA) oxidative damage, contributes to the development of coronary artery disease (CAD) in di...

    Authors: Xue-bin Wang, Ning-hua Cui, Xia’nan Liu and Xin Liu

    Citation: Cardiovascular Diabetology 2020 19:22

    Content type: Original investigation

    Published on:

  15. In the secondary prevention of cardiovascular (CV) disease in patients with diabetes, an optimal level of HbA1c, the most widely-used glycemic control indicator, for favorable clinical consequences still remai...

    Authors: Takehiro Funamizu, Hiroshi Iwata, Yuya Nishida, Katsutoshi Miyosawa, Shinichiro Doi, Yuichi Chikata, Jun Shitara, Hirohisa Endo, Hideki Wada, Ryo Naito, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Shinya Okazaki, Kikuo Isoda, Katsumi Miyauchi…

    Citation: Cardiovascular Diabetology 2020 19:21

    Content type: Original investigation

    Published on:

  16. Empagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular ...

    Authors: Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel and Valérie B. Schini-Kerth

    Citation: Cardiovascular Diabetology 2020 19:19

    Content type: Original investigation

    Published on:

  17. Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blo...

    Authors: Marco Witkowski, Mario Witkowski, Mona Saffarzadeh, Julian Friebel, Termeh Tabaraie, Loc Ta Bao, Aritra Chakraborty, Andrea Dörner, Bernd Stratmann, Diethelm Tschoepe, Samantha J. Winter, Andreas Krueger, Wolfram Ruf, Ulf Landmesser and Ursula Rauch

    Citation: Cardiovascular Diabetology 2020 19:20

    Content type: Original investigation

    Published on:

  18. Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better p...

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang and Edward Chia-Cheng Lai

    Citation: Cardiovascular Diabetology 2020 19:17

    Content type: Original investigation

    Published on:

  19. Cardiac adipose tissue may have local paracrine effects on epicardial arteries and the underlying myocardium, promoting calcification and affecting myocardial microcirculation. We explored whether the total am...

    Authors: Emilie H. Zobel, Regitse Højgaard Christensen, Signe A. Winther, Philip Hasbak, Christian Stevns Hansen, Bernt J. von Scholten, Lene Holmvang, Andreas Kjaer, Peter Rossing and Tine W. Hansen

    Citation: Cardiovascular Diabetology 2020 19:16

    Content type: Original investigation

    Published on:

  20. Heart-type fatty acid-binding protein (H-FABP) is a novel marker of myocardial injury and has been reported to be associated with cardiovascular diseases (CVD) including patients with diabetes mellitus (DM). U...

    Authors: Hui-Wen Zhang, Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Yan Zhang, Yuan-Lin Guo, Na-Qiong Wu, Ying Gao, Rui-Xia Xu, Qi Hua, Yan-Fang Li, Chuan-Jue Cui, Geng Liu, Qian Dong, Jing Sun and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2020 19:15

    Content type: Original investigation

    Published on:

  21. Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased car...

    Authors: Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel and Stefano Del Prato

    Citation: Cardiovascular Diabetology 2020 19:14

    Content type: Original investigation

    Published on:

  22. Sodium–glucose linked cotransporter-2 (SGLT2) inhibitors reduce the likelihood of hospitalization for heart failure and cardiovascular death in both diabetic and non-diabetic individuals with reduced ejection ...

    Authors: Kim A. Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N. Batchu, Verra G. Yerra, Golam Kabir, Kerri Thai, Andrew Advani and Richard E. Gilbert

    Citation: Cardiovascular Diabetology 2020 19:13

    Content type: Original investigation

    Published on:

  23. Type 2 diabetes increases the risk of coronary heart disease (CHD), yet the mechanisms involved remain poorly described. Polygenic risk scores (PRS) provide an opportunity to understand risk factors since they...

    Authors: Tianyuan Lu, Vincenzo Forgetta, Oriana H. Y. Yu, Lauren Mokry, Madeline Gregory, George Thanassoulis, Celia M. T. Greenwood and J. Brent Richards

    Citation: Cardiovascular Diabetology 2020 19:12

    Content type: Original investigation

    Published on:

  24. Insulin resistance may contribute to aortic stiffening that leads to end-organ damage. We examined the cross-sectional association and prospective association of insulin resistance and aortic stiffness in olde...

    Authors: Anna K. Poon, Michelle L. Meyer, Hirofumi Tanaka, Elizabeth Selvin, James Pankow, Donglin Zeng, Laura Loehr, Joshua W. Knowles, Wayne Rosamond and Gerardo Heiss

    Citation: Cardiovascular Diabetology 2020 19:11

    Content type: Original investigation

    Published on:

  25. Although a variety of antidiabetic drugs have significant protective action on the cardiovascular system, it is still unclear which antidiabetic drugs can improve ventricular remodeling and fundamentally delay...

    Authors: Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang and Feng Jiang

    Citation: Cardiovascular Diabetology 2020 19:10

    Content type: Original investigation

    Published on:

  26. To examine the incidence of atrial fibrillation in individuals with type 2 diabetes compared with age- and sex-matched controls from the general population and its variation in relation to glycaemic control an...

    Authors: Shilan Seyed Ahmadi, Ann-Marie Svensson, Aldina Pivodic, Annika Rosengren and Marcus Lind

    Citation: Cardiovascular Diabetology 2020 19:9

    Content type: Original investigation

    Published on:

  28. Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed...

    Authors: M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser and M. Arad

    Citation: Cardiovascular Diabetology 2020 19:7

    Content type: Original investigation

    Published on:

  29. The effect of sodium glucose cotransporter type 2 (SGLT2) inhibitor on left ventricular (LV) longitudinal myocardial function in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) has remained un...

    Authors: Hidekazu Tanaka, Fumitaka Soga, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi and Ken-ichi Hirata

    Citation: Cardiovascular Diabetology 2020 19:6

    Content type: Original investigation

    Published on:

  30. While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of ...

    Authors: Salva R. Yurista, Herman H. W. Silljé, Michiel Rienstra, Rudolf A. de Boer and B. Daan Westenbrink

    Citation: Cardiovascular Diabetology 2020 19:5

    Content type: Commentary

    Published on:

  31. This study investigated whether visit-to-visit fasting plasma glucose (FPG) variability, as measured by the coefficient of variation (CV), increased peripheral artery disease (PAD) risk.

    Authors: Chun-Pai Yang, Cheng-Chieh Lin, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Kai-Lin Hwang, Shing-Yu Yang and Tsai-Chung Li

    Citation: Cardiovascular Diabetology 2020 19:4

    Content type: Original investigation

    Published on:

  32. Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional...

    Authors: William A. E. Parker, Christian Schulte, Temo Barwari, Fladia Phoenix, Sam M. Pearson, Manuel Mayr, Peter J. Grant, Robert F. Storey and Ramzi A. Ajjan

    Citation: Cardiovascular Diabetology 2020 19:3

    Content type: Original investigation

    Published on:

  33. Peroxisome proliferator-activated receptor-γ (PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are ad...

    Authors: Chi-Hung Liu, Tsong-Hai Lee, Yu-Sheng Lin, Pi-Shan Sung, Yi-Chia Wei and Yan-Rong Li

    Citation: Cardiovascular Diabetology 2020 19:2

    Content type: Original investigation

    Published on:

  34. Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagli...

    Authors: Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose and Naoki Kumashiro

    Citation: Cardiovascular Diabetology 2020 19:1

    Content type: Original investigation

    Published on:

  35. It is unknown that dysglycemia in obese adolescents has effects on myocardial deformation that are more pronounced when compared to obesity alone. We hypothesized that obesity associated abnormal glucose toler...

    Authors: Preneet Cheema Brar, Anne Chun, Xiazhou Fan, Vivek Jani, Mary Craft, Puneet Bhatla and Shelby Kutty

    Citation: Cardiovascular Diabetology 2019 18:172

    Content type: Original investigation

    Published on:

  36. High-sensitivity troponin I (hs-Tnl) and B-type natriuretic peptide (BNP) are promising prognostic markers for coronary artery disease (CAD). This prospective cohort study investigated whether a combination of...

    Authors: Yuen-Kwun Wong, Chloe Y. Y. Cheung, Clara S. Tang, JoJo S. H. Hai, Chi-Ho Lee, Kui-Kai Lau, Ka-Wing Au, Bernard M. Y. Cheung, Pak-Chung Sham, Aimin Xu, Karen S. L. Lam and Hung-Fat Tse

    Citation: Cardiovascular Diabetology 2019 18:171

    Content type: Original investigation

    Published on:

  37. Glycemic variation has been suggested to be a risk factor for diabetes-related complications. Previous studies did not address confounding of diabetes duration, number of visits and length of follow-up. Here, ...

    Authors: Roderick C. Slieker, Amber A. W. H. van der Heijden, Giel Nijpels, Petra J. M. Elders, Leen M. ’t Hart and Joline W. J. Beulens

    Citation: Cardiovascular Diabetology 2019 18:170

    Content type: Original investigation

    Published on:

  38. HbA1c, the most commonly used indicator of chronic glucose metabolism, is closely associated with cardiovascular disease. However, the relationship between HbA1c and the mortality of acute coronary syndrome (A...

    Authors: Wenjun Pan, Haining Lu, Baotao Lian, Pengda Liao, Liheng Guo and Minzhou Zhang

    Citation: Cardiovascular Diabetology 2019 18:169

    Content type: Review

    Published on:

  39. The use of metformin after acute myocardial infarction (AMI) has been associated with reduced mortality in people with type 2 diabetes mellitus (T2DM). However, it is not known if it is acutely cardioprotectiv...

    Authors: Daniel I. Bromage, Tom R. Godec, Mar Pujades-Rodriguez, Arturo Gonzalez-Izquierdo, S. Denaxas, Harry Hemingway and Derek M. Yellon

    Citation: Cardiovascular Diabetology 2019 18:168

    Content type: Original investigation

    Published on:

  40. Omentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship ...

    Authors: Masami Nishimura, Tomoaki Morioka, Mariko Hayashi, Yoshinori Kakutani, Yuko Yamazaki, Masafumi Kurajoh, Katsuhito Mori, Shinya Fukumoto, Atsushi Shioi, Tetsuo Shoji, Masaaki Inaba and Masanori Emoto

    Citation: Cardiovascular Diabetology 2019 18:167

    Content type: Original investigation

    Published on:

  41. Type 2 diabetes mellitus (T2DM) is a major cause of heart failure (HF) with preserved ejection fraction (HFpEF), usually presenting as left ventricular (LV) diastolic dysfunction. Thus, LV diastolic function s...

    Authors: Shun Yokota, Hidekazu Tanaka, Yasuhide Mochizuki, Fumitaka Soga, Kentaro Yamashita, Yusuke Tanaka, Ayu Shono, Makiko Suzuki, Keiko Sumimoto, Jun Mukai, Makiko Suto, Hiroki Takada, Kensuke Matsumoto, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata

    Citation: Cardiovascular Diabetology 2019 18:166

    Content type: Original investigation

    Published on:

  42. Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their ...

    Authors: Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li and Tong Liu

    Citation: Cardiovascular Diabetology 2019 18:165

    Content type: Original investigation

    Published on:

  43. Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; however, its counter-protective effects have also been suggested in patients with heart failure and the clear explanation for...

    Authors: Aya Shiraki, Jun-ichi Oyama, Toshiyuki Nishikido and Koichi Node

    Citation: Cardiovascular Diabetology 2019 18:164

    Content type: Original investigation

    Published on:

  44. Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied. This study sought to determine the relationship between type...

    Authors: Kathleen Dungan, Jennifer Merrill, Clarine Long and Philip Binkley

    Citation: Cardiovascular Diabetology 2019 18:163

    Content type: Original investigation

    Published on:

  45. Statin therapy reduces the risk of cardiovascular events across a broad spectrum of patients; however, it increases the risk of new-onset diabetes (NOD). Although the highest dose pitavastatin is considered to...

    Authors: Han Saem Jeong, Soon Jun Hong, Serhim Son, Hyonggin An, Hyungdon Kook, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu and Do-Sun Lim

    Citation: Cardiovascular Diabetology 2019 18:162

    Content type: Original investigation

    Published on:

  46. The main aims of this study were to describe trends and outcomes during admission for infective endocarditis (IE) in people ≥ 40 years old with or without type 2 diabetes distributed in five time-periods (2001...

    Authors: José M. de Miguel-Yanes, Rodrigo Jiménez-García, Valentín Hernández-Barrera, Javier de Miguel-Díez, Manuel Méndez-Bailón, Nuria Muñoz-Rivas, Napoleón Pérez-Farinós and Ana López-de-Andrés

    Citation: Cardiovascular Diabetology 2019 18:161

    Content type: Original investigation

    Published on:

  47. Controversies exist regarding the optimal blood pressure (BP) level that is safe and provides cardiovascular protection in patients with type 2 diabetes mellitus (T2DM) and coexistent coronary artery disease. ...

    Authors: Ying Shen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Lin Lu, Feng Hua Ding and Wei Feng Shen

    Citation: Cardiovascular Diabetology 2019 18:160

    Content type: Review

    Published on:

  48. Microvascular complications (MC) have been claimed to increase the risk for cardiovascular disease in diabetic subjects. However, the effect of MC burden on the risk of major vascular outcomes and all-cause mo...

    Authors: Monia Garofolo, Elisa Gualdani, Rosa Giannarelli, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stefano Del Prato and Giuseppe Penno

    Citation: Cardiovascular Diabetology 2019 18:159

    Content type: Original investigation

    Published on:

  49. Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however re...

    Authors: Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda and Koichi Node

    Citation: Cardiovascular Diabetology 2019 18:158

    Content type: Original investigation

    Published on:

  50. Both type 1 and type 2 diabetes are well-established risk factors for cardiovascular disease and early mortality. However, few studies have directly compared the hazards of cardiovascular outcomes and prematur...

    Authors: You-Bin Lee, Kyungdo Han, Bongsung Kim, Seung-Eun Lee, Ji Eun Jun, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin and Jae Hyeon Kim

    Citation: Cardiovascular Diabetology 2019 18:157

    Content type: Original investigation

    Published on:

journal logo
Submit manuscript

Annual Journal Metrics

Cardiovascular Diabetology

ISSN: 1475-2840